Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study

Authors

Institutions

Publication Details

Journal
Inflammatory Bowel Diseases
Published
2024-10-25
DOI
https://doi.org/10.1093/ibd/izae253
Citations
22
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
12.11

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study

Remo Panaccione, Jordan Johns, Richard Moses, Joe Milata et al.
22 citations
Inflammatory Bowel Diseases
Inflammatory Bowel Disease
12.11
article

Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study

Remo Panaccione, Jordan Johns, Richard Moses, Joe Milata, Bruce E. Sands, Severine A.R.A. Vermeire, Marla C. Dubinsky, Peter Miles Irving, David B. Clemow, Tadakazu Hisamatsu, Taku Kobayashi, Geert D’Haens, Scott D. Lee, Corey A. Siegel, Maria T. Abreu, Axel Dignaß, Laurent Peyrin-Biroulet, Theresa Hunter Gibble
article en
22 citations

Abstract

No abstract available for this paper.
Inflammatory Bowel DiseasesVol. 31(7)
Dartmouth–Hitchcock Medical Center (US), University of Miami (US), Inserm (FR), Eli Lilly (United States) (US), University of Calgary (CA), King's College London (GB), Kyorin University (JP), Guy's and St Thomas' NHS Foundation Trust (GB), Universitair Ziekenhuis Leuven (BE), McGill University Health Centre (CA), University of Washington Medical Center (US), University of Miami Health System (US), Clinique Hartmann (FR), Agaplesion Markus Hospital (DE), Amsterdam University Medical Centers (NL), Kitasato Institute Hospital (JP), Nutrition-Génétique et Exposition aux Risques Environnementaux (FR), Kitasato University (JP), Icahn School of Medicine at Mount Sinai (US)
Eli Lilly and Company
Good health and well-being
Openalex Percentile: Top 1%
Inflammatory Bowel Disease
12.11
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.